antivirals

Merck sees up to $7B in coming sales of coronavirus pill
Merck sees up to $7B in coming sales of coronavirus pill
BioPharma Dive
Merck
COVID-19
antivirals
earnings
molnupiravir
Flag link:
Merck Inks Deal To Share Antiviral Covid Pill With Poorer Countries
Merck Inks Deal To Share Antiviral Covid Pill With Poorer Countries
Forbes
Merck
antivirals
COVID-19
molnupiravir
Flag link:
EMA starts rolling review of Merck's molnupiravir, continuing rapid regulatory response to COVID-19 antiviral data
EMA starts rolling review of Merck's molnupiravir, continuing rapid regulatory response to COVID-19 antiviral data
Fierce Biotech
Merck
molnupiravir
antivirals
COVID-19
Ridgeback Biotherapeutics
EMA
Flag link:
Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?
Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?
Motley Fool
Merck
antivirals
COVID-19
Gilead Sciences
Flag link:
Gates Foundation will provide $120 million to ensure generic production of Merck’s Covid-19 pill
Gates Foundation will provide $120 million to ensure generic production of Merck’s Covid-19 pill
Stat
Gates Foundation
generics
COVID-19
antivirals
Merck
molnupiravir
Flag link:
Atea’s antiviral pill fails to clear Covid-19, forcing a re-think
Atea’s antiviral pill fails to clear Covid-19, forcing a re-think
Stat
Atea Pharmaceuticals
COVID-19
antivirals
clinical trials
Roche
AT-527
Flag link:
Merck’s Covid-19 Pill Set for Review by FDA Advisory Panel
Merck’s Covid-19 Pill Set for Review by FDA Advisory Panel
Bloomberg
Merck
FDA
antivirals
COVID-19
molnupiravir
Flag link:
Merck’s breakthrough COVID pill faces a risk: the virus could outsmart it
Merck’s breakthrough COVID pill faces a risk: the virus could outsmart it
Fortune
Merck
COVID-19
molnupiravir
viral resistance
antivirals
Flag link:
Merck Reportedly Plans To Double Production Of New Covid-Fighting Pill As Wealthy Countries Corner Scarce Supplies
Merck Reportedly Plans To Double Production Of New Covid-Fighting Pill As Wealthy Countries Corner Scarce Supplies
Forbes
Merck
COVID-19
drug manufacturing
antivirals
molnupiravir
Flag link:
Merck asks FDA to authorize promising anti-COVID pill
Merck asks FDA to authorize promising anti-COVID pill
NPR
Merck
FDA
Ridgeback Therapeutics
COVID-19
antivirals
molnupiravir
Flag link:
Can This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment?
Can This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment?
Motley Fool
COVID-19
Merck
Ridgeback Therapeutics
Roche
Atea Pharmaceuticals
AT-527
antivirals
Flag link:
Merck May Beat Pfizer to the COVID Pill Market. Does It Matter?
Merck May Beat Pfizer to the COVID Pill Market. Does It Matter?
Motley Fool
Merck
Pfizer
antivirals
COVID-19
vaccines
Flag link:
Merck says research shows its COVID-19 pill works against variants
Merck says research shows its COVID-19 pill works against variants
Reuters
Merck
antivirals
molnupiravir
COVID-19
Delta COVID-19 variant
Flag link:
Pfizer starts trial of antiviral pill against COVID-19
Pfizer starts trial of antiviral pill against COVID-19
Biopharma Reporter
Pfizer
clinical trials
antivirals
COVID-19
Flag link:
Antiviral nasal drop maker does the Nasdaq shuffle as part of minor SPAC reverse merger
Antiviral nasal drop maker does the Nasdaq shuffle as part of minor SPAC reverse merger
Endpoints
Revelation Biosciences
antivirals
SPACs
NASDAQ
Flag link:
Merck kicks off oral COVID-19 antiviral filing in Canada
Merck kicks off oral COVID-19 antiviral filing in Canada
Pharmaforum
Merck
COVID-19
antivirals
Canada
Health Canada
molnupiravir
Flag link:
Gilead, Foresite back biotech developer of COVID-19 pill in latest SPAC deal
Gilead, Foresite back biotech developer of COVID-19 pill in latest SPAC deal
BioPharma Dive
antivirals
COVID-19
Gilead Sciences
Foresite
Pardes Biosciences
Flag link:
White House pledges $3 billion war chest for COVID antivirals
White House pledges $3 billion war chest for COVID antivirals
Pharmaforum
Joe Biden
pandemic
antivirals
COVID-19
Flag link:
This Biopharma Giant May Have Just Found Its Ticket To Riches In the COVID-19 Market
This Biopharma Giant May Have Just Found Its Ticket To Riches In the COVID-19 Market
Motley Fool
Merck
Ridgeback Biotherapeutics
COVID-19
molnupiravir
antivirals
Flag link:
Romark eyes FDA okay for COVID antiviral despite mixed trial results
Romark eyes FDA okay for COVID antiviral despite mixed trial results
Pharmaforum
Romark
antivirals
NT-300
clinical trials
COVID-19
Flag link:

Pages